Intelligence you can plan around

Speyside Group provides a strategic perspective on compassionate use regulations across Latin America, Africa, and Asia, mapping how patients with serious or life-threatening conditions access unapproved medicines outside a clinical trial. The analysis compares Brazil's RDC 38/2013, South Africa's Section 21, and Asia's more codified frameworks, and outlines the practical questions multinational pharmaceutical companies must answer before running a program in any given market.

Speyside Group provides a strategic perspective on how pharmaceutical companies influence healthcare policy in Latin America, mapping the seven principal channels of engagement across the region's leading regulatory and reimbursement bodies. Drawing on CONITEC data, Brazil's Partnerships for Productive Development, and coalition-building work with groups such as ERCAL and ILAR, the analysis shows why evidence generation and multi-stakeholder consensus consistently outperform formal lobbying in this market.

Speyside Group provides a strategic perspective on patient advocacy group engagement in emerging markets, examining how multinational pharmaceutical companies structure compliant, locally embedded partnerships across Latin America, Asia, and Africa. Drawing on cases from Brazil, India, and Ghana, the analysis outlines the funding caps, disclosure practices, and neutral-channel strategies that separate durable market access programs from reputational and regulatory risk.

Speyside Group analyzes the transformative "Great Healthcare Plan" of 2026, which has fundamentally redefined Pharmaceutical Market Access by linking U.S. drug pricing to international benchmarks. This shift toward a "glocal" strategy means that negotiation outcomes in Europe or APAC now act as a direct Global Price Anchor for the American market, effectively collapsing the divide between domestic and international pricing.

Speyside's Healthcare team forecasts that 2026 will be a year of structured reform, following a 2025 defined by sharp contrasts between rising geopolitical risks and scientific breakthroughs. As supply chains face pressure from tariffs and "Most Favoured Nation" policies, the industry requires robust Crisis management strategies to navigate pricing volatility. Our analysis highlights a critical shift in high-growth and emerging markets toward value-based healthcare, the integration of AI-driven diagnostics, and a renewed Corporate Affairs focus on the global infertility crisis.

The Speyside Healthcare team is analyzing the deepening crisis of Antimicrobial Resistance (AMR) in 2025, a systemic failure in global health governance that threatens emerging markets. With over 1.27 million deaths attributable to AMR annually and a fragile innovation pipeline, the crisis is driven by gaps in surveillance, poor economic incentives, and stalled National Action Plans. Addressing this requires sophisticated Corporate Affairs strategies to align pharmaceutical innovation, "One Health" governance, and sustainable financing models.

Spyeside team analyzes how investing in healthcare and establishing universal access pathways is crucial for accelerating societal and economic growth, especially in resource-constrained environments. Examples from the Global South demonstrate that universal coverage reforms and essential benefits packages not only improve health equity but also accelerate and sustain economic growth long-term.

Poland's healthcare funding gap & new EU funds create a high-growth market. Speyside Healthcare & Speyside Power Central Eastern Europe analyze the corporate affairs challenge of navigating this opportunity. Get the insight.

Barriers to adult vaccination in APAC create policy risks. Speyside Healthcare & Speyside Asia Pacific analyze the corporate affairs challenge. Get the insight.

Following Prabowo Subianto and Gibran Rakabuming Raka’s election victory, Indonesia is set for key policy shifts, especially in healthcare. Their agenda includes expanding medical faculties, modernizing hospitals, and easing access to medical technology. However, regulations like TKDN requirements, Halal certification, and strict compliance frameworks pose challenges to MedTech growth. Still, opportunities exist for foreign companies through local investment, partnerships, and advocacy for more inclusive policies. Speyside Asia Pacific analyzes the corporate affairs challenge for this emerging market. Get the insight.

Emerging markets face rising healthcare costs, aging populations, and limited budgets. A preventive, collaborative, and regulatory-focused approach is key for sustainable healthcare progress. The Speyside Healthcare team analyzes the corporate affairs challenge. Get the analysis.

The Speyside Latin America team is proud to have moderated the first Latin American Self-Care Congress was held in São Paulo, Brazil, bringing together regional and global leaders to promote self-care as a central element of public health policy. The event centered around the Declaration of São Paulo, which outlines seven key pillars to advance self-care and push for a future World Health Assembly resolution. This congress, culminating in the Declaration of São Paulo, is the result of five years of dedicated agenda-setting by the Speyside Healthcare team. It represents a major step forward in integrating self-care into public health policy, a core focus of our Corporate Affairs Latin America practice.